The importance of integrative medicine in oncological care is increasing in accordance with growth of its evidence base. In central Europe, white-berried mistletoe (Viscum album) preparations not only are among the most common types of treatments used in integrative medicine but also have been among of the most commonly prescribed cancer treatments in Germany per se in 2010 [1]. By 2017, mistletoe preparations will have been used in the treatment of cancer patients for 100 years. Mistletoe is a historic, folk remedy, but the first recorded use in oncology was by the Dutch physician Ita Wegman who used a mistletoe extraction for the treatment of a breast cancer patient following a recommendation by Rudolf Steiner [2]. The constituents of the mistletoe berry include lectins, viscotoxins, glycoproteins, oligo- and polysaccharides, and membrane lipids [3]. The PubMed database alone lists more than 1,200 citations for “mistletoe,” with approximately 50 new entries each year. There are a multitude of laboratory-based studies demonstrating immune stimulation, cytotoxicity, proapoptotic effects, antiangiogenesis, and DNA stabilisation [3–7]; animal experiments have found tumor-reducing effects [8]. Recent observations of a potent anti-inflammatory effect of Viscum album via selective inhibition of COX-2 protein expression provide a further rationale for an antitumor role of mistletoe in view of the close relationship between cancer and inflammation [9]. More recent research focuses on new mistletoe extracts that contain lipophilic components, that is, triterpenes, shown to have strong cytotoxic effects in mouse models [10].
Recent years have seen growth in the number and quality of clinical research studies on mistletoe therapy reporting improved patient outcomes, including studies of its coadministration alongside chemotherapy to reduce adverse effects and to improve quality of life in breast cancer, ovarian cancer, and lung cancer patients [11, 12]. Its clinical efficacy regarding tumor control and survival has been contested [13]; other systematic reviews have been more positive, particularly with regard to health-related quality of life outcomes [14]. A 2013 randomised-controlled trial reported an increase in median survival time for patients with pancreatic cancer [15]. Further similar well-designed clinical trials on other cancer types are warranted.
This special issue covers a wide range of research from basic science to clinical outcomes for cancer and other indications. We intend it to provide a scientific forum to promote further research and publication in this field.
We have included three articles dealing with the important subject of safety and quantification of adverse events of mistletoe therapy. P. J. Mansky and colleagues present the results of a National Center for Complementary and Alternative Medicine phase 1 dose escalation study of combined whole mistletoe extract and gemcitabine treatment in cancer patients and interactions between these two agents. In a prospective observational study, M. L. Steele and colleagues report safety data on subcutaneous mistletoe therapy in a large cancer population. Another article of this group focuses on the important and as yet underreported issue of the safety of off-label intravenous Viscum album administration.
In a Serbian randomized-controlled study, W. Tröger and colleagues measured the impact of concomitant mistletoe treatment with adjuvant chemotherapy on health-related quality of life in breast cancer patients. In an Italian randomized controlled phase 2 study, A. Longhi and colleagues investigated the effect of Viscum album treatment compared with standard epirubicin chemotherapy on survival and health-related quality of life in patients with osteosarcoma.
Shifting upstream to laboratory research, R. Kuonen and colleagues present new in vitro findings on the effect of a Viscum album lipophilic extract containing triterpenes on fibroblast migration, which serves as a wound healing model. S. Baumgartner and colleagues studied the effects of a traditional (anthroposophical) pharmaceutical process involving high-speed mixing of mistletoe extracts; they used an in vitro model to discern tumoricidal from host resistance mechanisms of action.
We hope this special issue contributes to the evidence base of mistletoe therapy and stimulates further robust research to establish its place in oncological treatment.
Acknowledgments
M. Kröz’s work was supported by the Humanus Institute, Berlin, and Software AG foundation, Darmstadt, Germany. G. Feder has received support from Helixor in the form of mistletoe and placebo ampoules for a trial and the University of Bristol was paid by Weleda for his chairing of UK Iscador prescribing guidelines.
Matthias Kröz
Gunver Sophia Kienle
Gene Feder
Srini Kaveri
Steven Rosenzweig